Amoy Diagnostics and Janssen China Sign MoU on Strategic Collaboration

Xiamen China, December 9, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) recently signed a Memorandum of Understanding (MoU) on strategic collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson. In this cooperation, both par

AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for Japan Market

Xiamen, China, Aug 19, 2021 - Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685), an innovative commercial-stage in vitro diagnostic (IVD) company, and Amgen Inc. (NASDAQ: AMGN), announced today that the companies have entered into a strategic collaboratio

AmoyDx^® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for TEPMETKO^® (tepotinib)

TOKYO and XIAMEN, August 17, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved the

AmoyDx^® Pan Lung Cancer PCR Panel Receives MHLW Approval as Companion Diagnostic for 9 Targeted Therapies for Use in Patients with Advanced Non-Small Cell Lung Cancer

TOKYO and XIAMEN, June 30, 2021 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the AmoyDx^® Pan Lung Cancer PCR Panel (the “AmoyDx^® PLC Panel”), an i

AmoyDx Signs Agreement with Haihe Biopharma to Co-develop Companion Diagnostics for the United States Market

Xiamen, China, March 12, 2021 – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) and Haihe Biopharma announced that they signed an agreement to use the MET mutation detection kit of AmoyDx as Companion Diagnostic (CDx) assay supporting the registration o

AmoyDx Collaborates with AstraZeneca to Co-develop HRD Companion Diagnostics for Ovarian Cancer

Xiamen, China, 19th February, 2021 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with AstraZeneca to develop a Homologous Recombination Deficiency (HRD) Companion Diagnostic (CDx) in ovarian cancer.

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for China Market

Xiamen, China, December 23, 2020 (12:30 pm) – Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepo

AmoyDx Signs Memorandum with AstraZeneca to Cooperate in Molecular Diagnostics in Gynecological Oncology worldwide

Xiamen, China, 16th November, 2020 – Recently Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) signed a collaborative memorandum with AstraZeneca in the third China International Import Expo.

AmoyDx EGFR Detection Method Won the 21st China's Top Patent Award

The EGFR mutation detection method from AmoyDx (Application No.: ZL200910111499.2, Publication No.: CN101608240B) won the Silver Award of the 21st China Patent Award as recently announced by the China National Intellectual Property Administration (CNIPA).

AmoyDx Collaborates with Haihe Pharmaceutical to Codevelop Companion Diagnostics for Japan Market

Xiamen, China, August 27, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Haihe Pharmaceutical to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor Glumetinib (SCC244). The CDx

AmoyDx Collaborates with Merck KGaA, Darmstadt, Germany to Develop Companion Diagnostics for Japan Market

Xiamen, China, 9:00am, August 10, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Merck KGaA, Darmstadt, Germany, to develop a Companion Diagnostic (CDx) test supporting the novel MET inhibitor tepotinib.

AmoyDx Signs Agreement with AstraZeneca to Cooperate in Cancer Diagnosis in China

Xiamen, China, 8 July, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that recently it signed an agreement with AstraZeneca to work together closely for the molecular diagnosis of patients with cancer.

AmoyDx Collaborates with Amgen to Develop Companion Diagnostics for China Market

Xiamen, China, 22 May, 2020– Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Amgen Inc. to develop Companion Diagnostic (CDx) tests supporting an investigational molecule within Amgen’s oncology portfolio. The

AmoyDx Announces Research Collaboration with Janssen to Develop Companion Diagnostics for China Market

Xiamen, China, 24 March, 2020–Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685) announced that it signed an agreement with Janssen (China) Research & Development Center, a Division of Johnson & Johnson (China) Investment Ltd., to develop an oncology compa

Latest News: Amoy Diagnostics born another clinical detecting center

Shanghai Xiawei Biotechnology Co. Laboratory (hereinafter referred to as "Shanghai Xiawei") under Amoy Diagnostics passed the examination of Shanghai Municipal Health Commission and was granted the "Practice License for Medical Institutions".

AmoyDx won the Second Prize of National Scientific and Technological Progress Award and National Enterprise Technology Center

AmoyDx won the Second Prize of National Scientific and Technological Progress Award; AmoyDx Technology Center is qualified as "National Enterprise Technology Center".

AmoyDx and Eisai Enter Global Diagnostic Partnership Agreement

Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE:300685), a leading company in companion diagnostics for precision oncology, today announced that recently it signed a diagnostic partnership agreement with Eisai Co., Ltd., one of leading pharmaceutical companies i

AmoyDx HANDLE Classic NGS Panel (HANDLE-LCP30) was recommended by ESMO as one of the NGS solutions capable of NTRK-fusion detection

Recently, the European Society for Medical Oncology (ESMO) Translational Research and Precision Medicine Working Group (TR and PM WG) launched a collaborative project to review the available methods that can be used to detect NTRK1/2/3 gene fusions.